vs

Side-by-side financial comparison of COMPX INTERNATIONAL INC (CIX) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $37.7M, roughly 2.0× COMPX INTERNATIONAL INC). COMPX INTERNATIONAL INC runs the higher net margin — 12.4% vs -121.9%, a 134.3% gap on every dollar of revenue. On growth, COMPX INTERNATIONAL INC posted the faster year-over-year revenue change (-1.9% vs -6.2%). COMPX INTERNATIONAL INC produced more free cash flow last quarter ($11.4M vs $9.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -0.4%).

COMPX International Inc. is a diversified manufacturer of security and control products, including high-performance locking systems, electronic access solutions, ergonomic workstation components, and marine hardware. It primarily serves North American and European markets, catering to commercial, residential, industrial, healthcare, and recreational marine segments.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CIX vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
2.0× larger
HCAT
$74.7M
$37.7M
CIX
Growing faster (revenue YoY)
CIX
CIX
+4.3% gap
CIX
-1.9%
-6.2%
HCAT
Higher net margin
CIX
CIX
134.3% more per $
CIX
12.4%
-121.9%
HCAT
More free cash flow
CIX
CIX
$1.8M more FCF
CIX
$11.4M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-0.4%
CIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CIX
CIX
HCAT
HCAT
Revenue
$37.7M
$74.7M
Net Profit
$4.7M
$-91.0M
Gross Margin
32.1%
Operating Margin
15.0%
-115.3%
Net Margin
12.4%
-121.9%
Revenue YoY
-1.9%
-6.2%
Net Profit YoY
3.6%
-340.3%
EPS (diluted)
$0.38
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIX
CIX
HCAT
HCAT
Q4 25
$37.7M
$74.7M
Q3 25
$40.0M
$76.3M
Q2 25
$40.4M
$80.7M
Q1 25
$40.3M
$79.4M
Q4 24
$38.4M
$79.6M
Q3 24
$33.7M
$76.4M
Q2 24
$35.9M
$75.9M
Q1 24
$38.0M
$74.7M
Net Profit
CIX
CIX
HCAT
HCAT
Q4 25
$4.7M
$-91.0M
Q3 25
$4.2M
$-22.2M
Q2 25
$5.5M
$-41.0M
Q1 25
$5.1M
$-23.7M
Q4 24
$4.5M
$-20.7M
Q3 24
$3.5M
$-14.7M
Q2 24
$4.8M
$-13.5M
Q1 24
$3.8M
$-20.6M
Gross Margin
CIX
CIX
HCAT
HCAT
Q4 25
32.1%
Q3 25
27.6%
52.6%
Q2 25
31.9%
Q1 25
30.2%
Q4 24
28.8%
Q3 24
28.1%
47.5%
Q2 24
31.1%
Q1 24
25.5%
Operating Margin
CIX
CIX
HCAT
HCAT
Q4 25
15.0%
-115.3%
Q3 25
11.9%
-22.9%
Q2 25
15.7%
-46.0%
Q1 25
14.6%
-25.4%
Q4 24
12.7%
-22.0%
Q3 24
9.9%
-17.9%
Q2 24
14.2%
-20.8%
Q1 24
9.8%
-30.5%
Net Margin
CIX
CIX
HCAT
HCAT
Q4 25
12.4%
-121.9%
Q3 25
10.6%
-29.1%
Q2 25
13.5%
-50.8%
Q1 25
12.7%
-29.9%
Q4 24
11.7%
-26.0%
Q3 24
10.3%
-19.3%
Q2 24
13.5%
-17.8%
Q1 24
9.9%
-27.6%
EPS (diluted)
CIX
CIX
HCAT
HCAT
Q4 25
$0.38
$-1.29
Q3 25
$0.34
$-0.32
Q2 25
$0.44
$-0.59
Q1 25
$0.42
$-0.35
Q4 24
$0.37
$-0.33
Q3 24
$0.28
$-0.24
Q2 24
$0.39
$-0.23
Q1 24
$0.31
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIX
CIX
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$54.1M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$138.6M
$245.8M
Total Assets
$156.2M
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIX
CIX
HCAT
HCAT
Q4 25
$54.1M
$95.7M
Q3 25
$46.3M
$91.5M
Q2 25
$56.2M
$97.3M
Q1 25
$56.1M
$342.0M
Q4 24
$60.8M
$392.0M
Q3 24
$58.8M
$387.3M
Q2 24
$82.1M
$308.3M
Q1 24
$75.6M
$327.8M
Total Debt
CIX
CIX
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
CIX
CIX
HCAT
HCAT
Q4 25
$138.6M
$245.8M
Q3 25
$137.7M
$331.9M
Q2 25
$149.5M
$347.5M
Q1 25
$147.6M
$376.8M
Q4 24
$146.1M
$365.2M
Q3 24
$145.3M
$355.0M
Q2 24
$170.2M
$357.0M
Q1 24
$168.9M
$357.2M
Total Assets
CIX
CIX
HCAT
HCAT
Q4 25
$156.2M
$502.6M
Q3 25
$153.7M
$587.1M
Q2 25
$164.8M
$616.2M
Q1 25
$162.2M
$891.5M
Q4 24
$163.0M
$858.9M
Q3 24
$160.1M
$813.0M
Q2 24
$185.1M
$691.7M
Q1 24
$181.7M
$695.1M
Debt / Equity
CIX
CIX
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIX
CIX
HCAT
HCAT
Operating Cash FlowLast quarter
$12.0M
$9.9M
Free Cash FlowOCF − Capex
$11.4M
$9.6M
FCF MarginFCF / Revenue
30.3%
12.9%
Capex IntensityCapex / Revenue
1.6%
0.4%
Cash ConversionOCF / Net Profit
2.57×
TTM Free Cash FlowTrailing 4 quarters
$19.1M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIX
CIX
HCAT
HCAT
Q4 25
$12.0M
$9.9M
Q3 25
$6.3M
$-464.0K
Q2 25
$4.7M
$-9.0M
Q1 25
$-137.0K
$280.0K
Q4 24
$7.3M
$-3.5M
Q3 24
$4.1M
$6.2M
Q2 24
$9.8M
$1.6M
Q1 24
$1.7M
$10.3M
Free Cash Flow
CIX
CIX
HCAT
HCAT
Q4 25
$11.4M
$9.6M
Q3 25
$5.3M
$-719.0K
Q2 25
$3.4M
$-9.2M
Q1 25
$-959.0K
$-390.0K
Q4 24
$7.1M
$-3.9M
Q3 24
$3.6M
$5.5M
Q2 24
$9.4M
$1.3M
Q1 24
$1.4M
$10.1M
FCF Margin
CIX
CIX
HCAT
HCAT
Q4 25
30.3%
12.9%
Q3 25
13.2%
-0.9%
Q2 25
8.4%
-11.4%
Q1 25
-2.4%
-0.5%
Q4 24
18.5%
-4.9%
Q3 24
10.8%
7.2%
Q2 24
26.2%
1.7%
Q1 24
3.6%
13.5%
Capex Intensity
CIX
CIX
HCAT
HCAT
Q4 25
1.6%
0.4%
Q3 25
2.5%
0.3%
Q2 25
3.3%
0.3%
Q1 25
2.0%
0.8%
Q4 24
0.6%
0.5%
Q3 24
1.4%
0.9%
Q2 24
1.2%
0.4%
Q1 24
0.8%
0.3%
Cash Conversion
CIX
CIX
HCAT
HCAT
Q4 25
2.57×
Q3 25
1.48×
Q2 25
0.87×
Q1 25
-0.03×
Q4 24
1.62×
Q3 24
1.18×
Q2 24
2.03×
Q1 24
0.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CIX
CIX

Security Products$29.5M78%
Marine Components$8.2M22%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons